Akcea Therapeutics, Inc.
https://akceatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akcea Therapeutics, Inc.
Finance Watch: VC Enthusiasm For Biopharma Continues As 5AM Ventures Raises $750m
Private Company Edition: 5AM revealed two funds totaling $450m and $300m, V-Bio raised a €110m venture capital fund and AXA IM Alts committed $500m for health care private equity deals. Also, TRIANA launched with $110m and the AMR Action Fund backs Adaptive Phage Therapeutics.
Finance Watch: Morningside Launches Adiso With More Than $60m In Early Funding
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
ANGPTL3 Road Has Some Potholes As Pfizer Sends Vupanorsen Back To Ionis
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.
US FDA Limits GMP Exemption For ‘N of 1’ Investigational New Drugs
Agency drafts guidance on how to apply requirements for chemistry, manufacturing and controls, and for good manufacturing practices, to bespoke antisense nucleotides.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides